Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 13, 2022 9:53am
119 Views
Post# 34820342

RE:RE:RE:RE:RE:Financing - ideal

RE:RE:RE:RE:RE:Financing - ideal

Then roughly buying $30mil principal will only cost around $24mil. Very smart use of proceeds. So there goes well over half the debt, half the interest for only $24 mil.


SPCEO1 wrote: Last trade was at $75.50
 

Wino115 wrote:

Dies anyone know the current price of the convertible (as of yesterday)? 

 

 

SPCEO1 wrote: If nothing else, it removes the overhang of another ONO from the stock. But will anyone even notice at this point? The stock should jump a lot on this deal because of the removed dilution overhang, the immediate benefit to cash flow over the next 2 years (maybe three years) and the backing of a major healthcare lender of TH's plans for the future. 
 

 

palinc2000 wrote:

Need to see the fine prints     

tee time in 5 minutes will look thid afternoon

 

SPCEO1 wrote: My initial reaction is this is perfect. The opposite of the ONO and indicative of confidence in the future of TH. I will have a closer look later.

 

 


 

 




<< Previous
Bullboard Posts
Next >>